Xconomy December 23, 2019
Dan Stanton

Pharma and software firms are actively embracing AI and machine learning, but governments may need to lead the way in accessing relevant data, says Molecular Health.

Molecular Health, a software firm focused on transforming big data into analysis and prediction tools for healthcare companies, believes biotech is in the early days of using artificial intelligence (AI) and machine learning in drug discovery and development.

It is not the technology available holding the industry back, but the managing and the monitoring of the data involved, according to Molecular Health CEO Friedrich von Bohlen.

“In certain parts of the process we can [embrace AI in R&D] already today, so it’s not so much a technology game, it’s really a data sharing and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Big Data, Govt Agencies, Pharma, Provider, Technology
Related Articles:
Zephyr AI Raises $111 Million in Series A Financing
Chatbot answers are all made up. This new tool helps you figure out which ones to trust.
AI degrades our work, nurses say
What If Generative AI Turned To Be A Flop In Healthcare?
A.C.C.E.S.S. AI: A New Framework For Advancing Health Equity In Health Care AI

Share This Article